Pfizer Inc. today said during its quarterly earnings call that it will file by the end of May for full Food and Drug Administration approval for its COVID-19 vaccine. More than 131 million doses of the Pfizer vaccine have been administered in the U.S. since it was authorized for emergency use in December. In seeking full authorization for adults ages 16 to 85, Pfizer is moving toward directly marketing the shot to consumers. Pfizer also indicated that it will seek FDA’s approval to change the agency’s existing storage guidance, enabling the vaccine to be kept at standard refrigerated temperatures for up to four weeks. The drug maker also expects a FDA decision soon on its application for the vaccine’s emergency use in adolescents aged 12 to 15.

Related News Articles

Headline
The Federal Emergency Management Agency is reminding stakeholders that funding is available under FEMA’s Public Assistance program, including for…
Headline
The Centers for Medicare & Medicaid Services today released an interim final rule requiring long-term care facilities in the Medicare and Medicaid…
Headline
The Food and Drug Administration today announced the expansion of its emergency use authorization for Pfizer’s COVID-19 vaccine to include adolescents ages 12…
Headline
Illinois health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence in…
Headline
Effective immediately, Medicare will pay $750 to administer monoclonal antibodies to COVID-19 patients in their residence or temporary lodging and increase…
Headline
The Centers for Disease Control’s independent advisory committee will meet May 12 for what’s expected to be a discussion of Pfizer’s request to authorize the…